Acumen Pharmaceuticals (ABOS) Income from Continuing Operations (2020 - 2026)
Acumen Pharmaceuticals (ABOS) reported Income from Continuing Operations of 21154000.0 for Q1 2026, up 26.86% on a YoY basis from 16675279.04 in Q1 2025, and up 15.26% sequentially from 24964000.0 in Q4 2025.
Acumen Pharmaceuticals (ABOS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 7 years of Income from Continuing Operations data on file, last reported at 21154000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 26.86% year-over-year to 21154000.0; the trailing twelve-month figure through Mar 2026 stood at 112841000.0 (up 3.41% YoY), and the FY2025 full-year result was 201858000.0, down 29.31% from the prior year.
- Income from Continuing Operations improved to 21154000.0 in Q1 2026, from 24964000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9244000.0 in Q1 2022 to a low of 51189000.0 in Q3 2022.
- A 5-year average of 23196588.24 and a median of 21569000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 1205.51% in 2022 and surged 74.77% in 2023, its largest moves.
- Tracing ABOS's Income from Continuing Operations over 5 years: stood at 14134000.0 in 2022, then slipped by 4.03% to 14704000.0 in 2023, then tumbled by 148.55% to 36547000.0 in 2024, then soared by 31.69% to 24964000.0 in 2025, then advanced by 15.26% to 21154000.0 in 2026.
- Business Quant data shows ABOS's Income from Continuing Operations at 21154000.0 in Q1 2026, 24964000.0 in Q4 2025, and 25942000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Acumen Pharmaceuticals | 140.03 Mn | 140.03 Mn | - | -21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.15 Mn |
| Dec 31, 2025 | -24.96 Mn |
| Sep 30, 2025 | -25.94 Mn |
| Jun 30, 2025 | -40.78 Mn |
| Mar 31, 2025 | -28.92 Mn |
| Dec 31, 2024 | -36.55 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -21.57 Mn |
| Mar 31, 2024 | -14.77 Mn |
| Dec 31, 2023 | -14.70 Mn |
| Sep 30, 2023 | -12.92 Mn |
| Jun 30, 2023 | -11.63 Mn |
| Mar 31, 2023 | -13.18 Mn |
| Dec 31, 2022 | -14.13 Mn |
| Sep 30, 2022 | -51.19 Mn |
| Jun 30, 2022 | -22.91 Mn |
| Mar 31, 2022 | -9.24 Mn |
| Dec 31, 2021 | -8.39 Mn |
| Sep 30, 2021 | -3.92 Mn |
| Jun 30, 2021 | -55.06 Mn |